Therapeutic options for regionally advanced non-small cell lung cancer

被引:14
|
作者
Buccheri, G [1 ]
Ferrigno, D [1 ]
机构
[1] A CARLE HOSP CHEST DIS,I-12100 CUNEO,ITALY
关键词
non-small cell lung cancer; locally advanced disease; chemotherapy; radiotherapy; surgery;
D O I
10.1016/0169-5002(96)00554-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The optimal treatment for regionally advanced non-small cell lung cancer (NSCLC, Stage IIIa/IIIb) remains unknown. Proposed approaches include surgery, radiotherapy, chemotherapy, and combinations of these. No treatment modality, however, has ever shown other than modest or minimal beneficial effects. When differences between new and old treatments appear trivial, as in the management of the locally advanced NSCLC, controlled studies are necessary to select the best approach. This review is based on a systematic overview of data from randomized trials comparing different treatment modalities. The following six points emerged from the cited literature. (1) It is sufficiently proved that chemotherapy alone prolongs survival in patients with both locally advanced and metastatic disease. (2) Although it is probably true that radiation therapy is better than no active treatment, this idea is supported by very limited evidence. (3) Although it is probably also true that radiotherapy alone is not worse than chemotherapy alone, this is another insufficiently proved issue. (4) The possible superiority of chemo-radiotherapy to chemotherapy alone or to supportive care is also poorly documented. (5) There is abundant evidence that chemo-radiotherapy is better than radiotherapy alone (however, this information may be unhelpful if point 2, or 3 remains unclarified). (6) Although neoadjuvant treatments have improved resectability and may ensure overall better results, the surgical cure, either alone or in combination with chemotherapy or chemo-radiotherapy, is another unproved option. Based on the above six points, it was concluded that new randomized studies are urgently needed to confirm the possible superiority of chemo-radiotherapy to chemotherapy. Only after such a validation, will the many ongoing trials, designed to prove the possible superiority of local surgical control to the more traditional approaches based on thoracic irradiation, have a practical sense.
引用
收藏
页码:281 / 300
页数:20
相关论文
共 50 条
  • [1] Therapeutic options for elderly patients with advanced non-small cell lung cancer
    Avery, Eric J.
    Kessinger, Anne
    Ganti, Apar Kishor
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 340 - 344
  • [2] Therapeutic options in patients with locally advanced non-small cell lung cancer
    Lampridis, Savvas
    Minervini, Fabrizio
    Scarci, Marco
    FRONTIERS IN SURGERY, 2024, 11
  • [3] Therapeutic options for oligoprogressive non-small cell lung cancer
    Gustin, P.
    Botticella, A.
    Tselikas, L.
    Mercier, O.
    Le Pechoux, C.
    Levy, A.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (04) : 519 - 526
  • [4] The Impact Of Renal Function On Therapeutic Options For Advanced Non-small Cell Lung Cancer (NSCLC)
    Cenik, B. K.
    Sun, H.
    Rasco, D. W.
    Gerber, D. E.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S244 - S244
  • [5] The impact of renal function on therapeutic options for advanced non-small cell lung cancer (NSCLC)
    Cenik, Bercin Kutluk
    Rasco, Drew Warren
    Sun, Han
    Gerber, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Therapeutic vaccines for advanced non-small cell lung cancer
    Cortes-Jofre, Marcela
    Rueda-Etxebarria, Mikel
    Orillard, Emeline
    Jimenez Tejero, Elena
    Rueda, Jose-Ramon
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (03):
  • [7] Therapeutic options following pneumonectomy in non-small cell lung cancer
    Petrella, Francesco
    Spaggiari, Lorenzo
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (08) : 919 - 925
  • [9] Emerging therapeutic agents for advanced non-small cell lung cancer
    Ruqin Chen
    Rami Manochakian
    Lauren James
    Abdel-Ghani Azzouqa
    Huashan Shi
    Yan Zhang
    Yujie Zhao
    Kexun Zhou
    Yanyan Lou
    Journal of Hematology & Oncology, 13
  • [10] Emerging therapeutic agents for advanced non-small cell lung cancer
    Chen, Ruqin
    Manochakian, Rami
    James, Lauren
    Azzouqa, Abdel-Ghani
    Shi, Huashan
    Zhang, Yan
    Zhao, Yujie
    Zhou, Kexun
    Lou, Yanyan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)